“The fact that no indication of any impact from the omega-3 fatty acids were found in this group, along with the results of other recent neutral trials, suggests that omega-3 supplements are ineffective for cardiovascular prevention,” said the ONEMI trial’s lead investigator. Dr. Are A. Kalstad of the Center for Clinical Research at Oslo University Hospital in Oslo, Norway.
Discussing the REDUCE-IT trail and the STRENGTH trial, Alberico Catapano, Ph.D., said it wasn’t clear whether the effect of the mineral oil or placebo would completely explain the difference between the two studies.
“The fact that no indication of any impact from the omega-3 fatty acids
were found in this group, along with the results of other recent neutral
trials, suggests that omega-3 supplements are ineffective for cardiovascular prevention,” said the ONEMI trial’s lead investigator. Dr. Are A. Kalstad of the Center for Clinical Research at Oslo University Hospital in Oslo,
Norway.
Discussing the REDUCE-IT trail and the STRENGTH trial, Alberico Catapano, Ph.D., said it wasn’t clear whether the effect of the mineral oil or placebo would completely explain the difference between the two studies.
“Given the current uncertain state of knowledge, neither patients nor
physicians can be confident that omega-3 fatty acids have any health
benefits, yet in 2019 the global market for omega-3 fatty acids reached $4.1 billion and is expected to double by 2025,” wrote deputy editor Dr.
Gregory Curfman.
http://www.ajc.com/life/fish-oil-not-found-to-reduce-risk-of-cardiac-event-according-to-study/BZNSROQHDVFGNF5Y7XAVTFLOPY/